– Interview with Michael West, Ph.D., Chief Executive Officer, BioTime, Inc.

PodcastsResourcesEmbryonic stem cellsGenetic engineeringGenetic Engineering and BiotechnologyMedicineMedicine, Diagnosis, and TherapeuticsPluripotent stem cellsRegenerative engineeringStem cell engineeringStem cellsTranslational medicine
Previous articleBayer Pays $90M for Maxygen’s Preclinical Hemophilia Program
Next articleCellectis Settles Dispute over Regeneron’s Use of Its Homologous Recombination Technology for up to $17.42 M